Kamada Ltd. , a plasma-derived protein therapeutics company focused on orphan indications, announces that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency , has designated the Company's proprietary human intrevenous Alpha-1 Antitrypsin as an orphan medicinal product to treat Graft-versus-host disease . In October 2014 Kamada received Orphan Drug designation from the U.S. Food and Drug Administration for its AAT by IV to treat GvHD.
http://ift.tt/1Ilzead
http://ift.tt/1Ilzead
No comments:
Post a Comment